Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

Next Previous
Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GOVX-B11 (Primary) ; HIV envelope protein gp120 modulators (Primary) ; HIV envelope protein gp120 modulators (Primary) ; MVA-HIV62 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 03 Aug 2021 Planned initiation date changed from 1 Sep 2020 to 1 Mar 2022.
  • 10 Aug 2020 According to a GeoVax Labs media release, management has expected that this trial would commence patient enrollment in late 2020, but now anticipates the trial to start during the first half of 2021 due to the trial sites being utilized for COVID-19 vaccine testing.
  • 06 May 2020 According to a GeoVax Labs media release, the start of this study is study has been delayed due to clarification of components other than our vaccine, but the company currently expects HVTN to commence patient enrollment in late 2020 or early 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top